576 related articles for article (PubMed ID: 22414450)
21. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
22. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
23. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
24. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.
Nguyen CT; Fu AZ; Gilligan TD; Wells BJ; Klein EA; Kattan MW; Stephenson AJ
J Clin Oncol; 2010 Jan; 28(1):119-25. PubMed ID: 19917846
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
27. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
Steiner H; Peschel R; Bartsch G
BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
[TBL] [Abstract][Full Text] [Related]
28. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
29. Management of clinical stage I nonseminomatous germ cell testicular cancer.
Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
[TBL] [Abstract][Full Text] [Related]
30. Management of Stage I Nonseminomatous Germ Cell Tumors.
Kovac E; Stephenson AJ
Urol Clin North Am; 2015 Aug; 42(3):299-310. PubMed ID: 26216817
[TBL] [Abstract][Full Text] [Related]
31. Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Stephenson AJ; Aprikian AG; Gilligan TD; Oldenburg J; Powles T; Toner GC; Waters WB
Urology; 2011 Oct; 78(4 Suppl):S444-55. PubMed ID: 21986224
[TBL] [Abstract][Full Text] [Related]
32. Stage I testicular cancer.
Scholz M; Höltl W
Curr Opin Urol; 2003 Nov; 13(6):473-6. PubMed ID: 14560141
[TBL] [Abstract][Full Text] [Related]
33. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
34. The role of retroperitoneal lymph node dissection in the management of testicular cancer.
Stephenson AJ; Sheinfeld J
Urol Oncol; 2004; 22(3):225-33; discussion 234-5. PubMed ID: 15271322
[TBL] [Abstract][Full Text] [Related]
35. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
36. Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I nonseminomatous germ-cell tumors.
Lowe BA
Urol Clin North Am; 1993 Feb; 20(1):75-83. PubMed ID: 8381999
[TBL] [Abstract][Full Text] [Related]
37. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
38. Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.
Heidenreich A; Paffenholz P; Nestler T; Pfister D; Daneshmand S
Curr Opin Urol; 2020 Mar; 30(2):251-257. PubMed ID: 31972635
[TBL] [Abstract][Full Text] [Related]
39. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors.
Chamie K; Kurzrock EA; Evans CP; Litwin MS; Koppie TM; Wootton-Gorges SL; Boone JM; Lara PN; Devere White RW
Cancer; 2011 Sep; 117(18):4219-30. PubMed ID: 21412759
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]